However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

Why: Depression is common in late life, effecting nearly five million of the 31 million Americans aged 65 and older. Both major and minor depression are reported in 13% of community dwelling older ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Presence of a protein-binding biomarker in a small cohort of adults with depression may be an indicator that suicidal ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...